基因沉默疗法治疗转甲状腺素蛋白淀粉样心肌病的结局试验荟萃分析
该荟萃分析纳入HELIOS-B和CARDIO-TTRansform两项随机安慰剂对照3期结局试验,共2086例ATTR-CM患者。
要点
- 基因沉默疗法降低ATTR-CM主要复合终点风险20%(RR 0.80),全因死亡风险26%(HR 0.74)。
- 基线未用TTR稳定剂者获益显著(RR 0.69),联用稳定剂者无显著增量获益(RR 0.97)。
- 基因沉默疗法还改善6分钟步行距离(+22.2 m)和KCCQ总分(+4.5)。
核心结论
- 荟萃分析结果支持TTR基因沉默疗法用于ATTR-CM。
- 联用TTR稳定剂者获益减弱可能反映病例组合、病程或TTR抑制幅度残余差异,或背景稳定治疗下基因沉默额外获益存在天花板效应。
研究设计与样本
- 检索PubMed截至2026年6月15日,纳入ATTR-CM基因沉默疗法的随机安慰剂对照3期结局试验。
- 共纳入2项研究(HELIOS-B和CARDIO-TTRansform),合计2086例ATTR-CM患者,其中1902例男性,中位年龄77岁(HELIOS-B范围45-85岁;CARDIO-TTRansform范围41-91岁)。
- 采用固定效应荟萃分析估计率比(RR)或风险比(HR)及95%CI,遵循PRISMA指南,两名评价者独立提取数据。
主要发现
- 基因沉默疗法降低全因死亡风险(HR 0.74;95%CI 0.61-0.91)和首次全因死亡或心血管事件时间风险(HR 0.77;95%CI 0.67-0.89)。
- 基因沉默疗法保留6分钟步行距离(安慰剂校正差值+22.2 m;95%CI 14.3-30.0)和KCCQ总分(+4.5;95%CI 2.7-6.2),无试验间异质性证据。
关键数值与推荐
- 主要终点:全因死亡和复发性心血管事件复合终点。
- 次要终点包括全因死亡、心血管死亡、首次主要终点时间、功能容量(6分钟步行距离)和健康状态(KCCQ总分)。
临床怎么用
- 对于ATTR-CM患者,基因沉默疗法可降低主要复合终点和全因死亡风险,并改善功能容量和健康状态。
- 基线未使用TTR稳定剂的患者可能从基因沉默疗法中获益更显著;联用稳定剂者增量获益不显著,临床决策需结合个体情况。
局限性
- 仅纳入2项试验,样本量有限。
- 基线稳定剂使用亚组间的获益异质性可能受病例组合、病程或TTR抑制幅度等残余混杂影响,不能确定为因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gene-silencing therapies reduce hepatic transthyretin (TTR) production and have been evaluated in phase 3 trials in TTR amyloid cardiomyopathy (ATTR-CM). However, differences in trial design and background therapies have limited assessment of the overall treatment effect and its consistency according to baseline TTR stabilizer use. OBJECTIVE: To assess the effect of TTR gene-silencing therapies in patients with ATTR-CM. DATA SOURCES AND STUDY SELECTION: PubMed was searched through June 15, 2026, for randomized, placebo-controlled, phase 3 outcome trials of gene-silencing therapies in ATTR-CM. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Fixed-effects meta-analysis estimated rate ratios (RRs) or hazard ratios (HRs) with 95% CIs. MAIN OUTCOMES AND MEASURES: The prespecified primary outcome was the composite of all-cause mortality and recurrent cardiovascular events. Secondary outcomes included all-cause mortality, cardiovascular death, time to first primary outcome, functional capacity (6-minute walk distance), and health status (Kansas City Cardiomyopathy Questionnaire-Overall Summary Score). RESULTS: A total of 2 studies (HELIOS-B and CARDIO-TTRansform) met the inclusion criteria and included 2086 patients with ATTR-CM. The studies included 1902 men with a median age of 77 years (range for HELIOS-B, 45-85 years; for CARDIO-TTRansform, 41-91 years). Gene-silencing therapy reduced the primary end point by 20% (RR, 0.80; 95% CI, 0.69-0.94; P = .006), with no heterogeneity between trials (P for heterogeneity = .28). Gene-silencing therapy also reduced the risk of all-cause death (HR, 0.74; 95% CI, 0.61-0.91) and time to first all-cause death or cardiovascular events (HR, 0.77; 95% CI, 0.67-0.89) compared with placebo. Gene silencers preserved 6-minute walk distance (placebo-corrected difference, +22.2 m; 95% CI, 14.3-30.0) and Kansas City Cardiomyopathy Questionnaire-Overall Summary Score (+4.5; 95% CI, 2.7-6.2), with no evidence of between-trial heterogeneity. Treatment effects on primary end points differed according to baseline stabilizer use, with significant benefits observed among patients not receiving background stabilizer therapy (RR, 0.69; 95% CI, 0.57-0.85) and no significant incremental benefit observed for those receiving concomitant stabilizer at baseline (RR, 0.97; 95% CI, 0.77-1.23; P for heterogeneity = .03). Similar heterogeneity was observed for functional capacity and health status. CONCLUSIONS AND RELEVANCE: The findings from this meta-analysis support TTR gene silencing for ATTR-CM. The attenuated benefit observed for patients receiving concomitant TTR stabilizer therapy may reflect residual differences in case mix, disease duration, or magnitude of TTR suppression or a true ceiling on additional benefit of gene silencing in the setting of background TTR stabilization. TRIAL REGISTRATION: PROSPERO registration: CRD420261421656. ClinicalTrials.gov Identifier: HELIOS-B, NCT04153149; and CARDIO-TTRansform, NCT04136171.
引用
- Gillmore JD, Hamatani Y, Fontana M, et al. Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials. JAMA. 2026. PMID: 42669065. doi:10.1001/jama.2026.17246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。